Merck & Co. highlights oncology pipeline, shares supported by long-term drug portfolio

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 14:23.

Merck & Co., Inc. (US58933Y1055) continues to lean on its oncology and vaccines franchises as key long-term earnings drivers. The company's flagship immuno-oncology drug KEYTRUDA remains central to growth expectations, with investors tracking its expanding indications alongside other pharmaceuticals listed on the NYSE.

KEYTRUDA and the cancer portfolio

Merck & Co., Inc. has built a broad oncology portfolio around KEYTRUDA, which is approved across multiple cancer types including melanoma, lung cancer, and head and neck tumors according to company disclosures. KEYTRUDA's mechanism as a PD-1 inhibitor has allowed Merck to pursue combination therapies and label extensions in several solid tumors.

Over recent years, Merck has reported steady growth in oncology revenues, with KEYTRUDA accounting for a significant share of total pharmaceutical sales as outlined in its latest annual and quarterly filings on the investor relations site. The company continues to invest heavily in clinical trials aimed at expanding use of KEYTRUDA in earlier cancer stages and additional indications, reinforcing the drug's role in its long-term strategy.

Vaccines and broader pharmaceutical base

Beyond oncology, Merck & Co., Inc. maintains a diversified portfolio including vaccines such as GARDASIL, which targets human papillomavirus (HPV), and other products in infectious diseases and chronic conditions. Its non-oncology portfolio provides additional recurring revenue streams and helps balance exposure to any single therapeutic area.

GARDASIL has seen robust global demand in recent years, particularly in markets with established vaccination programs, contributing meaningfully to Merck's overall revenue mix. Together with other vaccines and hospital acute care products, this business segment supports Merck's long-term cash flow generation and complements its oncology focus.

The product behind the stock

Merck & Co., Inc.'s representative product in oncology is KEYTRUDA, a monoclonal antibody targeting the PD-1 pathway in cancer immunotherapy. It is used to treat multiple tumor types and is a key component of Merck's long-term revenue and research focus.

Where the stock trades today

Merck & Co., Inc. shares trade on the NYSE under the ticker MRK. As of 2026-06-27, 14:23, the last verifiable share price and market cap data were not conclusively available from live sources, so only the listing venue is reported without a current price figure.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.